{
    "clinical_study": {
        "@rank": "37087", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and antiviral HBV activity of\n      ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase\n      1 and 2 Studies in Chronic Hepatitis B Infection."
        }, 
        "brief_title": "Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.", 
        "completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Evaluation of safety and antiviral activity of the 5mg dose of ACH-126,443 for up to three\n      months of treatment in the population described."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants in previous Phase 1 or 2 trials of ACH-126,443 who met entry criteria\n             for previous studies.\n\n          -  Adults ? 18 years of age\n\n          -  Chronic HBV infection, known to be HbsAg positive ? 6 months\n\n          -  Plasma HBV DNA level ? 100,000 copies/mL prior to initiation of ACH-126,443 in an\n             earlier study\n\n          -  Plasma HBV DNA level that in the medical judgment of the investigator, warrant's\n             antiviral treatment\n\n          -  HIV negative\n\n          -  Basic hematologic and chemistry parameters within acceptable limits (defined in\n             protocol)\n\n          -  No need for excluded medications\n\n          -  Subjects of reproductive capability must either practice abstinence or utilize two\n             approved forms of birth control, one of which must be barrier protection (condom with\n             spermicidal, diaphragm with spermicidal)\n\n        Exclusion Criteria\n\n          -  HIV infection\n\n          -  Active Hepatitis C co-infection\n\n          -  Concurrent systemic antiviral treatment\n\n          -  Treatment for HBV infection with lamivudine (3TC) for longer than three (3) months\n             since participation in previous trial of ACH-126,443\n\n          -  Previous therapy with agents with significant systemic myelosuppressive or cytotoxic\n             potential within 3 months of study start or the expected need for such therapy at\n             study start\n\n          -  Alcohol abuse\n\n          -  Pregnancy or breast-feeding\n\n          -  Inability to tolerate oral medication\n\n          -  AST>10.0 times the upper limit of normal\n\n          -  ALT>10.0 times the upper limit of normal\n\n          -  Any clinical condition or prior therapy that, in the Investigators opinion, would\n             make the subject unsuitable for the study or unable to comply with the dosing\n             requirements\n\n          -  Use of investigational drug not approved by Medical Monitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "May 17, 2002", 
        "id_info": {
            "nct_id": "NCT00037622", 
            "org_study_id": "ACH443-901"
        }, 
        "intervention": {
            "intervention_name": "ACH-126, 443 (beta-L-Fd4C)", 
            "intervention_type": "Drug"
        }, 
        "keyword": "E-antigen positive, treatment na\u00efve chronic HBV infected, lamivudine resistant chronic Hepatitis B, Achillion", 
        "lastchanged_date": "August 18, 2009", 
        "link": {
            "url": "http://www.achillion.com"
        }, 
        "official_title": "An Open-Label Treatment Protocol to Provide Continued ACH-126,443 to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037622"
        }, 
        "source": "Achillion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Achillion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2009", 
        "why_stopped": "Safety concerns from other studies."
    }, 
    "geocoordinates": {}
}